Atrial fibrillation and warfarin use in haemodialysis patients: An individualized holistic approach is important in stroke prevention

Abstract

Incidence and prevalence of atrial fibrillation (AF) is higher in haemodialysis (HD) population than general population. AF is associated with higher morbidity and mortality than sinus rhythm in this population. The purpose of this review is to summarize all available evidence regarding use of warfarin in HD patients with AF for stroke prevention. The enormous heterogeneity of available studies does not allow pooling of the data in the form of meta-analysis or systematic review. Current evidence regarding use of warfarin for AF in terms of risk benefit ratio in this population is limited and conflicting. Randomized control trials evaluating the safety and efficacy of anticoagulation in this population by means of risk/benefit assessment tools are urgently needed. However, suitable HD patients with AF should be counselled on their likelihood of reduction of stroke risk and experiencing side-effects before initiating anticoagulant therapy. It is particularly important to incorporate the patient's preferences and willingness to trade off benefit and risk in stroke prevention. An individualized holistic approach optimizing all potential risk factors of bleeding and ischemic stroke in HD patients with AF is recommended. Summary at a Glance Atrial fibrillation is more common in patients on haemodialysis yet the therapeutic value of warfarin remains inconclusive. An individualized approach taking into consideration of potential risk versus benefit should always be adopted when anti-coagulative therapy is examined. © 2013 The Authors. Nephrology © 2013 Asian Pacific Society of Nephrology.